Compare AIIO & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIIO | ZVRA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United Arab Emirates | United States |
| Employees | 29 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.1M | 562.2M |
| IPO Year | N/A | 2015 |
| Metric | AIIO | ZVRA |
|---|---|---|
| Price | $3.00 | $11.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 886.9K | ★ 1.4M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $15.62 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $0.07 | $7.16 |
| 52 Week High | $9.20 | $15.04 |
| Indicator | AIIO | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | N/A |
| Support Level | $2.60 | N/A |
| Resistance Level | $4.96 | N/A |
| Average True Range (ATR) | 0.25 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 51.08 | 0.00 |
Robo.ai Inc is a decentralized, AI-powered intelligent mobility platform that integrates smart vehicles, robotics, and blockchain technologies. The company is developing an AI-NAS ecosystem focused on delivering a passenger-centric platform by combining hardware and software, leveraging onboard computing, and offering an open cloud environment. Its product portfolio includes MUSE, a full-sized autonomous electric SPV; GHIATH, a purpose-built vehicle for public services and law enforcement developed in collaboration with Dubai Police; and Astra, an autonomous logistics vehicle. It also offers other vehicle models such as NWONE (SUV), Rabdan One (SUV), and Rabdan Seven (MPV) in the UAE through the SKD model. The company operates across the USA, UAE, and Mainland China.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.